Phase-changeable nanoparticles loaded with Fe III -tannic acid/paclitaxel for retinoblastoma treatment

Li Bin,Yangrui Du,Yu Zhang,Qibin Xiao,Xiaoli Chen,Zhongshun Liu,Zhiyu Du
DOI: https://doi.org/10.1016/j.jddst.2022.103989
IF: 5
2022-11-15
Journal of Drug Delivery Science and Technology
Abstract:In this study, phase-changeable nanoparticles consisting of poly(lactic- co -glycolic acid) (PLGA) shells with Fe III -tannic acid (Fe III TA), paclitaxel (PTX), and perfluorinated pentane (PFP) were prepared, and their therapeutic effect on retinoblastoma (RB) was evaluated. The killing effect of the Fe III TA/PLGA/PTX/PFP (FPTP) + laser (FPTP + laser) treatment on Y79 cells was stronger than that of the blank control, laser, and FPTP treatments. Moreover, this effect increased with increasing concentration. In vivo experiments showed that the nanoparticles clustered at the tumor sites in mice and that laser excitation produced heat. The tumor volume increased gradually over time in the blank control and laser groups but not in the PTX, PLGA/PTX/PFP + laser, and FPTP groups. The FPTP + laser group showed the best tumor-volume-reduction results. The results collectively suggest that FPTP nanoparticles have good therapeutic effects on RB and may potentially be applied as a new integrated approach for RB diagnosis and treatment. Graphical abstract A new strategy for combined diagnostic imaging and treatment of retinoblastomas was demonstrated. Nanoparticles constructed from poly(lactic-co-glycolic acid) (PLGA) shells with Fe III -tannic acid (Fe III TA), perfluorinated pentane (PFP), and the chemotherapy drug paclitaxel were shown to target retinoblastoma cells in vivo and in vitro. With laser irradiation, these FPTP nanoparticles effectively inhibited tumor cell proliferation and reduced tumor volumes. Download : Download high-res image (280KB) Download : Download full-size image
pharmacology & pharmacy
What problem does this paper attempt to address?